Bendamustine is a unique bifunctional alkylating agent with a purine-like benzimidazole ring. It is a cytotoxic chemotherapeutic agent used primarily in the treatment of hematological malignancies. Its mechanism combines alkylating properties with antimetabolite-like activity, leading to DNA damage via single-strand and double-strand breaks, and activation of apoptosis pathways. In India, it is a key therapy for Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL), particularly where fludarabine-based regimens have failed or are unsuitable.
Adult: CLL & NHL: 100 mg/m² body surface area (BSA) administered by IV infusion over 30 minutes on Days 1 and 2 of a 28-day cycle, for up to 6 cycles. Dose may be reduced to 50-75 mg/m² based on tolerance. Multiple Myeloma: 75-100 mg/m² on Days 1 and 2 of each 28-day cycle (with prednisone).
Note: Reconstitute the 100mg vial with 20 mL of Sterile Water for Injection (resulting concentration 5 mg/mL). Further dilute in 500 mL of 0.9% Sodium Chloride Injection (preferred) or 2.5% Dextrose/0.45% Sodium Chloride Injection to a final concentration of 0.2-0.6 mg/mL. Administer IV infusion over 30-60 minutes. Do not mix with other medications. Use within 24 hours of reconstitution when stored refrigerated (2-8°C). Premedicate with antihistamine (e.g., diphenhydramine), antipyretic (e.g., paracetamol), and corticosteroid (e.g., dexamethasone) 30-60 minutes prior.
Bendamustine's unique structure confers a dual mechanism: 1) Alkylation of DNA via its nitrogen mustard groups, causing intra-strand and inter-strand cross-links, leading to DNA strand breaks. 2) Its benzimidazole ring acts as a purine analogue, potentially disrupting mitotic checkpoints and metabolism. This combined action induces apoptosis through p53-independent pathways and is active against cells resistant to other alkylating agents.
Pregnancy: Category D. May cause fetal harm. Can cause teratogenicity and embryolethality based on mechanism. Women of childbearing potential must use effective contraception during and for at least 3 months after therapy. Men with female partners must use condoms during and for 6 months after therapy.
Driving: Fatigue, dizziness, and somnolence are common. Patients should be cautioned against driving or operating machinery if they experience these effects.
| Fludarabine | Increased risk of severe pulmonary toxicity (fatalities reported). Avoid concomitant use. | Major |
| CYP1A2 Inhibitors (e.g., Ciprofloxacin, Fluvoxamine) | May increase bendamustine exposure and toxicity. Monitor closely. | Moderate |
| CYP1A2 Inducers (e.g., Omeprazole, Smoking) | May decrease bendamustine exposure and efficacy. Monitor response. | Moderate |
| Allopurinol | May increase risk of severe skin reactions. Use with caution. | Moderate |
| Live Vaccines | Risk of disseminated infection. Contraindicated during treatment. | Major |
| Other Myelosuppressive Agents | Additive bone marrow toxicity. Monitor blood counts intensively. | Major |